Bupropion as a drug of first choice in monotherapy and a complement to therapies that do not cause complete remissions – point of view of a practicing psychiatrist Case report
Article Sidebar
Published:
Dec 31, 2023
Keywords:
bupropion, bipolar disorder, depression, monotherapy, case report, elderly
Main Article Content
Abstract
The paper presents case reports of the bupropion treatment of complicated depressive disorders. The first case describes treatment of the depression associated with long-term bipolar disorder with seasonal features, while in the second describes recurrent depression associated with retirement. In both cases, bupropion was safe and effective.
Article Details
How to Cite
Sokół-Szawłowska, M. (2023). Bupropion as a drug of first choice in monotherapy and a complement to therapies that do not cause complete remissions – point of view of a practicing psychiatrist. Medycyna Faktow (J EBM), 16(4(61), 423-427. https://doi.org/10.24292/01.MF.0423.21
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Fava M, Rush AJ, Thase ME et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7: 106-13.
2. Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry. 1983; 44(Sec 2): 67-73.
3. Baune BT, Florea I, Ebert B et al. Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study. Neuropsychiatr Dis Treat. 2021; 17: 2995-3006. http://doi.org/10.2147/NDT.S325954.
4. Li DJ, Tseng PT, Chen YW et al. Significant treatment effect of bupropion in patients with bipolar disorder but similar phase-shifting rate as other antidepressants. A meta-analysis following the PRISMA guidelines. Medicine. 2016; 95(13): 1-8.
5. Rybakowski J. Farmakoterapia choroby afektywnej dwubiegunowej. In: Jarema M (ed). Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wyd. 3. Via Medica, Gdańsk 2022.
6. Yildiz M, Batmaz S, Songur E et al. State of the art psychopharmacological treatment options in seasonal affective disorder. Psychiatr Danub. 2016; 28(1): 25-9.
7. Drozd K, Święcicki Ł. Choroba afektywna sezonowa. Medycyna po Dyplomie. 2014; 1.
8. Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry. 2001; 16: 862-5.
9. Hajizadeh A, Howes S, Theodoulou A et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023; 5: CD000031. http://doi.org/10.1002/14651858.CD000031.pub6.
10. Dwoskin LP, Rauhut AS, King-Pospisil KA et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006; 12(3-4): 178-207. http://doi.org/10.1111/j.1527-3458.2006.00178.x.
11. Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357-66. http://doi.org/10.4088/jcp.v63n0414.
12. Montejo AL, Prieto N, de Alarcón R et al. Management strategies for antidepressant-related sexual dysfunction: a clinical approach. J Clin Med. 2019; 8(10): 1640. http://doi.org/10.3390/jcm8101640.
13. Gałecki P, Bliźniewska-Kowalska K. Depresja oporna na leczenie – zalecenia Konsultanta Krajowego w dziedzinie psychiatrii. Psychiatr Pol. 2021; 55(1): 7-21.
2. Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry. 1983; 44(Sec 2): 67-73.
3. Baune BT, Florea I, Ebert B et al. Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study. Neuropsychiatr Dis Treat. 2021; 17: 2995-3006. http://doi.org/10.2147/NDT.S325954.
4. Li DJ, Tseng PT, Chen YW et al. Significant treatment effect of bupropion in patients with bipolar disorder but similar phase-shifting rate as other antidepressants. A meta-analysis following the PRISMA guidelines. Medicine. 2016; 95(13): 1-8.
5. Rybakowski J. Farmakoterapia choroby afektywnej dwubiegunowej. In: Jarema M (ed). Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wyd. 3. Via Medica, Gdańsk 2022.
6. Yildiz M, Batmaz S, Songur E et al. State of the art psychopharmacological treatment options in seasonal affective disorder. Psychiatr Danub. 2016; 28(1): 25-9.
7. Drozd K, Święcicki Ł. Choroba afektywna sezonowa. Medycyna po Dyplomie. 2014; 1.
8. Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry. 2001; 16: 862-5.
9. Hajizadeh A, Howes S, Theodoulou A et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023; 5: CD000031. http://doi.org/10.1002/14651858.CD000031.pub6.
10. Dwoskin LP, Rauhut AS, King-Pospisil KA et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006; 12(3-4): 178-207. http://doi.org/10.1111/j.1527-3458.2006.00178.x.
11. Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357-66. http://doi.org/10.4088/jcp.v63n0414.
12. Montejo AL, Prieto N, de Alarcón R et al. Management strategies for antidepressant-related sexual dysfunction: a clinical approach. J Clin Med. 2019; 8(10): 1640. http://doi.org/10.3390/jcm8101640.
13. Gałecki P, Bliźniewska-Kowalska K. Depresja oporna na leczenie – zalecenia Konsultanta Krajowego w dziedzinie psychiatrii. Psychiatr Pol. 2021; 55(1): 7-21.